556 related articles for article (PubMed ID: 23828131)
21. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
[No Abstract] [Full Text] [Related]
22. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.
Griessenauer CJ; Lebensburger JD; Chua MH; Fisher WS; Hilliard L; Bemrich-Stolz CJ; Howard TH; Johnston JM
J Neurosurg Pediatr; 2015 Jul; 16(1):64-73. PubMed ID: 25837886
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
Cunningham-Myrie C; Abdulkadri A; Waugh A; Bortolusso Ali S; King LG; Knight-Madden J; Reid M
Pediatr Blood Cancer; 2015 Oct; 62(10):1862-4. PubMed ID: 25929458
[TBL] [Abstract][Full Text] [Related]
25. Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia.
Brousse V; Gandhi S; de Montalembert M; Height S; Dick MC; O'Driscoll S; Abihsera G; Rees DC
Br J Haematol; 2013 Jan; 160(2):259-61. PubMed ID: 23116405
[No Abstract] [Full Text] [Related]
26. Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia.
Champlin G; Hwang SN; Heitzer A; Ding J; Jacola L; Estepp JH; Wang W; Ataga KI; Owens CL; Newman J; King AA; Davis R; Kang G; Hankins JS
Exp Biol Med (Maywood); 2021 Dec; 246(23):2473-2479. PubMed ID: 34407676
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
[TBL] [Abstract][Full Text] [Related]
28. [Effectiveness and acceptance of hydroxyurea in the treatment of severe forms of sickle cell disease: a prospective study of 65 cases].
Mellouli F; Chouaibi S; Dhouib N; Ouederni M; Ben Khaled M; Abbes S; Bejaoui M
Tunis Med; 2013; 91(8-9):544-50. PubMed ID: 24227514
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea and sickle cell anemia: effect on quality of life.
Ballas SK; Barton FB; Waclawiw MA; Swerdlow P; Eckman JR; Pegelow CH; Koshy M; Barton BA; Bonds DR
Health Qual Life Outcomes; 2006 Aug; 4():59. PubMed ID: 16942629
[TBL] [Abstract][Full Text] [Related]
30. [Sickle cell anemia in children: value of hydroxyurea in severe forms].
Oury AP; Hoyoux C; Dresse MF; Chantraine JM
Arch Pediatr; 1997 Sep; 4(9):839-44. PubMed ID: 9345564
[TBL] [Abstract][Full Text] [Related]
31. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
Keikhaei B; Yousefi H; Bahadoram M
Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
Rodgers GP
Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
[TBL] [Abstract][Full Text] [Related]
33. Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease.
Mack AK; Thompson AA
J Pediatr Health Care; 2017; 31(2):145-154. PubMed ID: 27423528
[TBL] [Abstract][Full Text] [Related]
34. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
[TBL] [Abstract][Full Text] [Related]
35. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
[TBL] [Abstract][Full Text] [Related]
36. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
[TBL] [Abstract][Full Text] [Related]
37. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
38. Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.
Upadhye DS; Jain DL; Trivedi YL; Nadkarni AH; Ghosh K; Colah RB
PLoS One; 2016; 11(1):e0147081. PubMed ID: 26785407
[TBL] [Abstract][Full Text] [Related]
39. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
40. Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.
Belini Junior E; Silva DG; Torres Lde S; Okumura JV; Lobo CL; Bonini-Domingos CR
Blood Cells Mol Dis; 2015 Apr; 54(4):321-7. PubMed ID: 25842370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
